Phosphate Homeostasis, Inflammation and the Regulation of FGF-23 by Lang, Florian et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Phosphate Homeostasis, Inflammation and the Regulation of FGF-23
Lang, Florian; Leibrock, Christina; Pandyra, Aleksandra A; Stournaras, Christos; Wagner, Carsten A;
Föller, Michael
Abstract: Fibroblast growth factor 23 (FGF23) is released primarily from osteoblasts/osteocytes in bone.
In cooperation with the transmembrane protein Klotho, FGF23 is a powerful inhibitor of 1￿ 25OH Vita-
min D Hydroxylase (Cyp27b1) and thus of the formation of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). As
1,25(OH)2D3 up-regulates intestinal calcium and phosphate absorption, the downregulation of 1,25(OH)2D3
synthesis counteracts phosphate excess and tissue calcification. FGF23 also directly inhibits renal phos-
phate reabsorption. Other actions of FGF23 include triggering of cardiac hypertrophy. FGF23 formation
and/or release are stimulated by 1,25(OH)2D3, phosphate excess, Ca2+, PTH, leptin, catecholamines,
mineralocorticoids, volume depletion, lithium, high fat diet, iron deficiency, TNF￿ and TGFß2. The
stimulating effect of 1,25(OH)2D3 on FGF23 expression is dependent on RAC1/PAK1 induced actin-
polymerisation. Intracellular signaling involved in the stimulation of FGF23 release also includes increases
in the cytosolic Ca2+ concentration ([Ca2+]i) following intracellular Ca2+ release and store-operated
Ca2+ entry (SOCE). SOCE is accomplished by the Ca2+ release-activated calcium channel protein 1
(Orai1) and its stimulator stromal interaction molecule 1 (STIM1). Expression of Orai1, SOCE and
FGF23-formation are up-regulated by the proinflammatory transcription factor NF￿B. The present brief
review describes the cellular mechanisms involved in FGF23 regulation and its sensitivity to both phos-
phate metabolism and inflammation. The case is made that up-regulation of FGF23 by inflammatory
mediators and signaling may amplify inflammation by inhibiting formation of the anti-inflammatory
1,25(OH)2D3.
DOI: https://doi.org/10.1159/000495393
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-159842
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Lang, Florian; Leibrock, Christina; Pandyra, Aleksandra A; Stournaras, Christos; Wagner, Carsten A;
Föller, Michael (2018). Phosphate Homeostasis, Inflammation and the Regulation of FGF-23. Kidney
Blood Pressure Research, 43(6):1742-1748.
DOI: https://doi.org/10.1159/000495393
 Kidney Blood Press Res 2018;43:1742-1748
DOI: 10.1159/000495393
Published online: 23 November 2018
© 2018 The Author(s). Published by S. Karger AG, Basel
www.karger.com/kbr 1742
Lang et al.: Regulation of FGF23 Release
Review
Accepted: 14 November 2018
This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Interna-
tional License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution 
for commercial purposes as well as any distribution of modified material requires written permission.
© 2018 The Author(s) 
Published by S. Karger AG, Basel
www.karger.com/kbr
Phosphate Homeostasis, Inflammation and 
the Regulation of FGF-23
Florian Langa    Christina Leibrockb    Aleksandra A. Pandyrac    Christos Stournarasd    
Carsten A. Wagnere    Michael Föllerf
aDepartment of Physiology I, Eberhard-Karls University Tübingen, bFresenius Kabi Deutschland 
GmbH, Bad Homburg, cDepartment of Molecular Medicine II, Heinrich Heine University Duesseldorf, 
Duesseldorf, Germany, dDepartment of Biochemistry, University of Crete Medical School, Heraklion, 
Greece, eInstitute of Physiology, NCCR Kidney.CH, University of Zürich, Zürich, Switzerland, fUniversity 
of Hohenheim, Institute of Physiology, Stuttgart, Germany
Key Words
1,25(OH)2D3 • Orai1 • iron deficiency • TNFα • TGFβ2
Abstract
Fibroblast growth factor 23 (FGF23) is released primarily from osteoblasts/osteocytes in bone. 
In cooperation with the transmembrane protein Klotho, FGF23 is a powerful inhibitor of 1α 
25OH Vitamin D Hydroxylase (Cyp27b1) and thus of the formation of 1,25-dihydroxyvitamin 
D3 (1,25(OH)2D3). As 1,25(OH)2D3 up-regulates intestinal calcium and phosphate absorption, the 
downregulation of 1,25(OH)2D3 synthesis counteracts phosphate excess and tissue calcification. 
FGF23 also directly inhibits renal phosphate reabsorption. Other actions of FGF23 include 
triggering of cardiac hypertrophy. FGF23 formation and/or release are stimulated by 1,25(OH)2D3, 
phosphate excess, Ca2+, PTH, leptin, catecholamines, mineralocorticoids, volume depletion, 
lithium, high fat diet, iron deficiency, TNFα and TGFß2. The stimulating effect of 1,25(OH)2D3 
on FGF23 expression is dependent on RAC1/PAK1 induced actin-polymerisation. Intracellular 
signaling involved in the stimulation of FGF23 release also includes increases in the cytosolic 
Ca2+ concentration ([Ca2+]i) following intracellular Ca2+ release and store-operated Ca2+ entry 
(SOCE). SOCE is accomplished by the Ca2+ release-activated calcium channel protein 1 (Orai1) 
and its stimulator stromal interaction molecule 1 (STIM1). Expression of Orai1, SOCE and FGF23-
formation are up-regulated by the proinflammatory transcription factor NFκB. The present brief 
review describes the cellular mechanisms involved in FGF23 regulation and its sensitivity to both 
phosphate metabolism and inflammation. The case is made that up-regulation of FGF23 by 
inflammatory mediators and signaling may amplify inflammation by inhibiting formation of the 
anti-inflammatory 1,25(OH)2D3.
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IntroductionFibroblast growth factor 23 (FGF23) is primarily released from bone [1], to a lesser extent from the spleen and brain [1], and, under pathophysiological conditions, from other organs, including kidney [2]. FGF23 adjusts the regulation of calcium and phosphate metabolism to 
the mineralization of bone [1]. FGF23 down-regulates renal 1α 25OH vitamin D hydroxylase 
(Cyp27b1) and thus curtails the formation of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) 
[1]. Moreover, FGF23 accelerates 1,25(OH)2D3 degradation by the up-regulation of 
25-hydroxyvitamin D 24-hydroxylase (Cyp24) [1]. As 1,25(OH)2D3 is a powerful stimulator of intestinal absorption and renal reabsorption of calcium and phosphate, the downregulation 
of 1,25(OH)2D3 by FGF23 decreases plasma calcium and phosphate concentrations [1]. Furthermore, FGF23 directly inhibits the renal phosphate reabsorption and thus enhances renal phosphate excretion [1]. FGF23 thus limits intestinal phosphate uptake and increases renal phosphate elimination when bone mineralization is abundant [1]. FGF23 release is 
further stimulated by 1,25(OH)2D3 or activation of the vitamin D receptor (VDR), a negative 
feedback loop contributing to the limitation of 1,25(OH)2D3 formation [1].
The effect of FGF23 on renal 1,25(OH)2D3 formation requires the cooperation with the 
co-receptor Klotho [1]. 1,25(OH)2D3, calcium and phosphate plasma levels are excessive 
in mice deficient in either FGF23 or Klotho leading to severe tissue calcification [1, 3, 4], 
and a variety of disorders including deranged bone mineralization, growth deficit, cardiac 
hypertrophy, emphysema, hypogonadism, infertility, hearing loss, cognitive impairment, decreased physical performance, thymus atrophy, reduced fat tissue and sarcopenia [1, 2]. 
As a result, life span is dramatically decreased in FGF23- or Klotho-deficient animals [1]. 
The tissue calcification is not simply due to calcium phosphate super-saturation, but results 
from the triggering of osteogenic/chondrogenic trans-differentiation of affected cells [5]. 
In Klotho-deficient mice, the excessive formation of 1,25(OH)2D3 is followed by dramatic 
increases in FGF23 release and plasma levels [1].
Parathyroid hormone (PTH) is another powerful stimulator of FGF23 synthesis 
and release. PTH acts in bone via the orphan nuclear receptor Nurr1 to enhance FGF23 
transcription. Thereby, PTH enhances renal phosphate excretion directly and indirectly 
via FGF23. FGF23, in turn, suppresses PTH secretion in a Klotho-dependent manner, a 
mechanism defective in patients with chronic kidney disease with reduced levels of Klotho.
The present brief review discusses cellular mechanisms involved in the regulation of 
FGF23 formation/release and its involvement in inflammatory disease.
Stimulators of FGF23 release
In addition to excess of phosphate and 1,25(OH)2D3, enhanced extracellular Ca2+ 
concentrations, parathyroid hormone (PTH), leptin, catecholamines, mineralocorticoids, 
volume depletion, lithium, inflammation, iron deficiency, high fat diet, TNFα and TGFß2 
stimulate FGF23 release from bone [1, 6-13]. The increase of FGF23 plasma levels following 
high-fat diet is at least partially due to upregulation of TNFα [12].
In chronic kidney disease (CKD), FGF23 plasma levels are typically elevated prior 
to development of hyperphosphatemia and hyperparathyroidism [1, 14]. Common 
complications of CKD include inflammation and iron deficiency, both stimulators of FGF23 
production in bone [11]. In contrast to Klotho-deficient mice, 1,25(OH)2D3 plasma levels are 
decreased in CKD [2, 15]. Thus, 1,25(OH)2D3 cannot account for the excessive FGF23 plasma 
levels in CKD. Treatment of uremic rats with neutralizing anti-FGF23 antibodies restores 
1,25(OH)2D3 plasma levels, but aggravates hyperphosphatemia and increases mortality 
[14]. FGF23 plasma concentrations are further enhanced in polycystic kidney disease [16], diabetic nephropathy [17], shiga toxin- induced hemolytic uremic syndrome [18] and nephrotic syndrome [19].
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Cellular mechanisms regulating FGF23 releaseFGF23 formation and release are inhibited by the phosphate-regulating gene with 
homology to endopeptidase (PHEX) and dentin matrix protein or cyclin D binding myb-
like protein 1 (DMP-1) [1]. Loss of function mutations of PHEX or DMP-1 lead to dramatic 
increases in FGF23 release from bone with increased circulating levels of FGF23 [20, 
21]) impaired 1,25(OH)2D3 formation, renal phosphate wasting, hypophosphatemia, and 
impairment of bone mineralization [21-24], as amplified below.
The stimulating effect of 1,25(OH)2D3 on FGF23 expression requires polymerized actin 
filaments which are regulated by the pro-inflammatory transcription factor nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-kB), ras-related C3 botulinum toxin substrate 1 (Rac1) and p21 protein-activated kinase 1 (PAK1) [25].
NFκB stimulates the expression of Orai1, a Ca2+ channel activated by the Ca2+ sensor STIM1 following Ca2+ depletion of intracellular Ca2+ stores [26]. Orai1/STIM1 thus affect store-operated Ca2+ entry (SOCE) [26]. Osteoblasts express Orai1, and SOCE in those cells 
is disrupted by pharmacological inhibition of either NFκB or Orai1 [26]. Stimulation of 
SOCE enhances FGF23 expression, an effect mimicked by the Ca2+ ionophore ionomycin 
[26]. Conversely, FGF23 expression is suppressed by pharmacologic or siRNA-mediated 
knockout of Orai1, as well as pharmacologic inhibition of NFκB [26]. Thus, FGF23 formation is up-regulated by Ca2+ entry through NFκB-dependent Orai1 [26]. As phosphate-induced 
osteogenic/chondrogenic transdifferentiation involves TGFß and NFκB [27, 28], it is 
tempting to speculate that TGFß, NFκB-activity, Orai1 expression and SOCE contribute to 
the phosphate-induced stimulation of FGF23 formation. However, further experiments are required to fully elucidate the role of this signaling pathway in the stimulation of FGF23 by phosphate.
NFκB-activity, Orai1 expression and SOCE are upregulated by aldosterone-inducible 
serum & glucocorticoid inducible kinase SGK1 [29]. Aldosterone up-regulates SOCE and FGF23 formation in osteoblasts. The effect of aldosterone on FGF23 expression is abrogated by blockage of the mineralocorticoid receptor and by pharmacological inhibition 
of SGK1, NFκB, and Orai1 [30]. FGF23 plasma concentration in mice increases following 
administration of the mineralocorticoid DOCA or by salt depletion [30]. Renal salt loss and 
extracellular volume depletion probably account for the enhanced FGF23 plasma levels in 
mice lacking functional thiazide-sensitive NaCl transporter NCC [10], mice which express 
the inactive Ste20-Related Proline/Alanine-Rich Kinase (SPAK) [31] or mice expressing 
the inactive oxidative stress-responsive kinase (OSR) [32]. It is unclear whether enhanced 
FGF23 levels in annexin 7- deficient mice [33] are due to volume depletion or inflammation.
NFκB-activity, Orai1 expression and SOCE are further up-regulated by treatment of 
osteoblasts with lithium [34]. Lithium-treatment enhances FGF23 plasma concentrations in 
both mice [35] and humans [36]. The effect of lithium on FGF23 in osteoblasts is disrupted by 
pharmacological inhibition of Orai1 und NFκB. Lithium thus stimulates FGF23 expression/
release at least in part by stimulating NFκB with subsequent up-regulation of Orai1 and 
SOCE [34].
Orai1 expression and SOCE are downregulated by the energy sensing AMP-activated 
kinase (AMPK) [37, 38]. Accordingly, FGF23 gene transcription is enhanced in AMPKα1-
knockout mice [39]. FGF23 gene transcription in UMR106 osteoblast-like cells is decreased 
by the AMPK activator, 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) and 
increased by the AMPK inhibitor, dorsomorphin dihydrochloride (compound C) [39].
The up-regulation of FGF23 by inflammation and iron-deficiency involves activation of 
hypoxia-inducible factor (HIF)-1α [40].
CO-releasing molecule (CORM-2) stimulates FGF23 release in vivo and in vitro [41] thus 
decreasing the formation of 1,25(OH)2D3 [41].
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FGF23 cleavage
FGF23 plasma levels are a function not only of FGF23 formation/release, but as well of 
FGF23 cleavage [13].  FGF23 cleavage is stimulated by iron deficiency [40] and the enhanced 
formation of FGF23 in iron deficiency is thus paralleled by enhanced FGF23 cleavage [40]. 
In autosomal dominant hypophosphatemic rickets (ADHR) gain-of-function mutations in 
FGF23 prevent the proteolytic FGF23 cleavage leading to phosphate wasting [13]. The extent 
depends on the rate of FGF23 formation which is enhanced by iron deficiency [13].
Clinical significance of FGF23 excess
The excessive increase of plasma FGF23 concentrations, compromized 1,25(OH)2D3 formation and renal phosphate wasting in patients carrying loss of function mutations of 
PHEX [20, 22]) interferes with bone mineralization leading to several clinical disorders including limb deformity, short stature, arthritis, enthesopathy, hearing impairment, optic atrophy and nephrocalcinosis [21-24]. Loss of function mutations of DMP-1 lead to  rickets/osteomalacia later during childhood or in adulthood [23].
The FGF23 excess in Klotho deficient mice is paralleled by pathological cardiac 
remodeling with left ventricular hypertrophy and myocardial fibrosis [42], activated cardiac 
Fgf23/Fgf receptor (Fgfr) 4/calcineurin/nuclear factor of activated T cell (NFAT) signaling, 
induction of pro-hypertrophic NFAT target genes including Rcan1, bMHC, brain natriuretic peptide (BNP), and atrial natriuretic peptide (ANP), activated cardiac ERK1/2 and enhanced 
expression of Tgf-β1, collagen I, and Mmp2 [42]. Those effects are not observed in other mice 
with excessive FGF23 and may require hyperphosphatemia and hypercalcemia [42].
FGF23 in the regulation of inflammation
The sensitivity of FGF23 formation to TGFß2, TNFα and the pro-inflammatory 
transcription factor NFκB links FGF23 release and 1,25(OH)2D3-formation to inflammation 
(Fig. 1). As a matter of fact, the effects of 1,25(OH)2D3 are not limited to regulation of mineral 
metabolism but affect a variety of functions including inhibition of 
inflammation [43-46]. It is tempting to speculate that the stimulation of 
FGF23 by inflammation functions as an amplifyer, as it suppresses the 
formation of the anti-inflammatory 
1,25(OH)2D3. Along those lines, the enhanced release of FGF23 
during inflammation [47] and mineralocorticoid excess could explain the enigmatic association between enhanced FGF23 plasma 
levels and the unfavorable course of 
several diseases including CKD [2].
Clearly, additional investigations are warranted to elucidate the impact 
of the FGF23/1,25(OH)2D3 axis on 
inflammatory disease. Fig. 1. Regulation of FGF23 and its impact on inflammation. 
Abbreviations: Cat = catecholamines, CKD = chronic kidney 
disease, DH = dehydration, Fe Def = iron deficiency, HFD = 
high fat diet, MC = mineralocorticoids, Pi = phosphate.
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Conclusion
Stimulators of FGF23 formation and release include 1,25(OH)2D3, phosphate excess, Ca2+, PTH, leptin, catecholamines, mineralocorticoids, volume depletion, lithium, high 
fat diet, iron deficiency, TNFα and TGFß2. Signaling involved in the stimulation of FGF23 
formation includes RAC1/PAK1 dependent actin-polymerisation and up-regulation of the 
transcription factor NFκB followed by increased expression of Ca2+ channel protein Orai1 and its stimulator STIM, which accomplish store operated Ca2+ entry (SOCE). The sensitivity 
of FGF23 formation to TNFα, TGFß2 and the proinflammatory transcription factor NFκB 
establishes a link between mineral metabolism and inflammation.
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